AI Insight
New research examines the efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors in adults aged 80 years and older with chronic kidney disease. The study suggests that advanced age does not prevent patients from experiencing the therapeutic benefits of this class of medications. The findings will be presented at ASN Kidney Week 2026, indicating preliminary research results.
Why it matters
This research addresses an important gap in treating elderly CKD patients, a population often underrepresented in clinical trials and excluded from treatments due to age-related concerns. If validated, these findings could expand treatment options for a vulnerable patient population that faces high rates of kidney disease progression and cardiovascular complications.
Understand the Science
New research uncovers the potential benefits and risks of sodium-glucose cotransporter 2 (SGLT2) inhibitors for adults aged 80 years or older with chronic kidney disease (CKD). The findings will be presented at ASN Kidney Week 2026, Oct. 22–25.